Idenix Raises $26.2M

Xconomy Boston — 

Idenix Pharmaceuticals (NASDAQ: IDIX), a Cambridge, MA-based developer of anti-viral drugs, has priced an offering of 6.46 million shares of its common stock at $4.35 per share, an SEC filing revealed. Thomas Weisel Partners is acting as the sole book-running manager of the deal, which will bring in net proceeds of about $26.2 million to Idenix, according to a company announcement. The funding will go to general corporate purposes, research and development expenses, and potential acquisitions.